INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
SEC FORM 4/Grant or awardVerified data

Babarczy Julian Michael reported ATHE

Director · ALTERITY THERAPEUTICS LTD · ALTERITY THERAPEUTICS LTD — Unlisted option exp 15 Jun 2031

Side
A
Value
—
Shares
2.00M
Price
—
Executed
Jun 15, 2026
Disclosed
Jun 23, 2026
Disclosure timeline8 days from execution to publication · legal deadline 2 business days
Jun 15 executedJun 23, 2026 disclosed

ATHE · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
19/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing+10 / 15

    Disclosed 6 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ATHE

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    56
    MA
    Marks Peter AshleyDirector
    ATHEALTERITY THERAPEUTICS LTD
    Open-market purchase
    		BUY$24K
    47.6K sh
    		Aug 31, 2026Sep 8, 2026
    traded Aug 31, 2026
    		+8dSEC FORM 4

    Evidence

    52
    MA
    Marks Peter AshleyDirector
    ATHEALTERITY THERAPEUTICS LTD
    Open-market purchase
    		BUY$24K
    47.6K sh
    		Aug 31, 2026Sep 8, 2026
    traded Aug 31, 2026
    		+8dSEC FORM 4

    Evidence

    56
    SA
    Stamler David AllenDirector, Chief Executive Officer
    ATHEALTERITY THERAPEUTICS LTD
    Open-market purchase
    		BUY$24K
    47.6K sh
    		Aug 31, 2026Sep 8, 2026
    traded Aug 31, 2026
    		+8dSEC FORM 4

    Evidence

    19
    GB
    Gozlan Lawrence BernardDirector
    ATHEALTERITY THERAPEUTICS LTD
    Grant or award
    		A—
    1.00M sh
    		Jun 15, 2026Jun 23, 2026
    traded Jun 15, 2026
    		+8dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002127744-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jun 15, 2026
    Published
    Jun 23, 2026
    Ingested by INSIDER
    Nov 5, 03:51 UTC
    Last re-read
    Nov 5, 03:51 UTC

    Extracted facts

    Filer
    Babarczy Julian Michael
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    ALTERITY THERAPEUTICS LTD — Unlisted option exp 15 Jun 2031
    Ticker
    ATHE
    Shares
    2.00M
    Price per share
    $0
    Execution date (reported)
    Jun 15, 2026
    Owned after transaction
    2.00M shares
    Days from execution to publication
    8

    What this establishes

    Babarczy Julian Michael filed this Form 4 reporting a grant or award of ATHE on Jun 15, 2026. It became public on Jun 23, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Babarczy Julian Michaelcik:0002127744
    Issuer
    ALTERITY THERAPEUTICS LTDcik:0001131343

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.